March 11, 2021, CommBio Therapeutics, a biotech focusing on developing intestine biology-driven novel medicine, announced strategic collaboration with Hangzhou Grand Biologic Pharmaceutical, a leading company in microbial live biotherapeutics in China.

Recently, increasing scientific evidence strongly indicated a causal role of gut microbiota in various diseases including infectious disease, cancer, neurological disease, immune disease, metabolic disease and so on. Utilizing bacteria to modulate intestine function and disease signal is a new and promising therapeutic strategy to treat such diseases. In the past few years, intestinal bacterial biotherapeutic products (LBPs) have shown high potential in clinical test and drawn tremendous attention in the drug discovery industry.

The agreement comes with equity investment and technology platform collaboration. The two companies will team up to develop gut bacterial LBPs to benefit the patients who are waiting for the safe, effective and affordable treatment.